Search

Displaying results 3381 - 3390 of 10000 in total
  1. Drug

    Sennosides

    go.drugbank.com/drugs/DB11365
    ApprovedInvestigational

    It is a weaker laxative than bisacodyl or castor oil[A177092]. … The medication is taken by mouth or via the rectum[FDA Label]. It typically begins working in minutes when given by rectum and within twelve hours when given by mouth[FDA Label].

    Mixtures: 2 In 1laxative Stool Softener and Stiulant Laxative, 2 In 1laxative Stool Softener and Stiulant Laxative
  2. Target

    3-oxoacyl-[acyl-carrier-protein] synthase 2

    go.drugbank.com/bio_entities/BE0000800
    TargetEscherichia coli (strain K12)

    Involved in the type II fatty acid elongation cycle (PubMed:6988423, PubMed:9013860). Catalyzes the elongation of a wide range of acyl-ACP by the addition of two carbons from malonyl-ACP to an acyl acceptor (PubMed:22017312, PubMed:90138...

    Synonyms: KAS II
  3. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. … Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant.

  4. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

  5. Drug

    Didecyldimethylammonium

    go.drugbank.com/drugs/DB04221
    ApprovedInvestigational

    Mixtures: Septi-san
  6. Drug

    SOBI-003

    go.drugbank.com/drugs/DB15451
    Investigational

    It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients). … SOBI-003 is a chemically modified variant of a recombinant human sulfamidase.

  7. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). … Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans [A32565].

  8. Target

    Alpha-1 adrenergic receptors

    go.drugbank.com/bio_entities/BE0004863
    TargetHumans

    Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenge...

    Polypeptides: Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptorSynonyms: Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c
  9. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada. … LHON is a mitochondrially inherited degeneration of retinal ganglion cells, resulting in acute central vision loss.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

    Categories: Adrenergic beta-2 Receptor Agonists